Table 2.
Treatments of IEI patients with TM infections
| Patients | Antifungal | Anti-TB | Other treatments |
|---|---|---|---|
| P1 | VCZ, AmB, ITZ, FCZ | INH, RFP, PZA, LNZ | IVIG |
| P2 | VCZ, AmB | INH, RFP | CoSMZ, GCV, IVIG |
| P3 | VCZ, ITZ, AmB | – | CoSMZ, GCV, IVIG |
| P4 | VCZ, MCFG, AmB, ITZ | INH, RFP, PZA | ACV, DXM, IVIG |
| P5 | VCZ, AmB, ITZ | – | CoSMZ, IVIG |
| P6 | VCZ | INH, RFP, PZA, LNZ | MP, VP-16, CoSMZ, IVIG |
| P7 | AmB, ITZ | – | – |
| P8 | VCZ, ITZ | – | – |
IEI inborn errors of immunity, TM T. marneffei, AmB amphotericin B, VCZ voriconazole, ITZ itraconazole, FCZ fluconazole, MCFG micafungin, INH isoniazid, RFP rifampicin, PZA pyrazinamide, LNZ linezolid, CoSMZ compound sulfamethoxazole and trimethoprim, AZM azithromycin, GCV ganciclovir, ACV acyclovir, DXM dexamethasone, MP methylprednisolone, VP-16 etoposide, IVIG intravenous immunoglobulin